Who
Lewis H. Bender
President and CEO
Company insider
Files Form 4 as: President and CEO, Intensity Therapeutics; Chief Executive Officer, Interleukin Genetics; Chief Technology Officer, Emisphere Technologies.
In numbers
- Trades disclosed
- 26
- Buys
- 5
- Sells
- 0
- Bought
- $24K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 28 Dec 2006
- Last trade
- 16 Jul 2026
- Last filed
- 20 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 20 Jul 2026 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,000 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,000 at $0.00 | filing |
| 26 Mar 2026filed 30 Mar 2026 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $231K37,749 at $6.11 | filing |
| 26 Mar 2026filed 30 Mar 2026 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $231K37,749 at $6.11 | filing |
| 2 May 2025filed 6 May 2025 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 6 Mar 2024filed 7 Mar 2024 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —464,805 at $0.00 | filing |
| 6 Mar 2024filed 7 Mar 2024 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,574 at $0.00 | filing |
| 14 Feb 2011filed 16 Feb 2011 | Interleukin Geneticsoption or derivative | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 21 Jan 2010filed 22 Jan 2010 | Interleukin Geneticsoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 13 Mar 2009filed 16 Mar 2009 | Interleukin Genetics | SEC FORM 4 Code A | $30K110,000 at $0.27 | filing |
| 24 Nov 2008filed 24 Nov 2008 | Interleukin Genetics | SEC FORM 4 Bought | $24100 at $0.24 | filing |
| 24 Nov 2008filed 24 Nov 2008 | Interleukin Genetics | SEC FORM 4 Bought | $1,1254,500 at $0.25 | filing |
| 24 Nov 2008filed 24 Nov 2008 | Interleukin Genetics | SEC FORM 4 Bought | $3,85015,400 at $0.25 | filing |
| 21 Nov 2008filed 24 Nov 2008 | Interleukin Genetics | SEC FORM 4 Bought | $2,70010,000 at $0.27 | filing |
| 20 Nov 2008filed 20 Nov 2008 | Interleukin Genetics | SEC FORM 4 Bought | $2,6358,235 at $0.32 | filing |
| 20 Nov 2008filed 20 Nov 2008 | Interleukin Genetics | SEC FORM 4 Bought | $5821,765 at $0.33 | filing |
| 20 Nov 2008filed 20 Nov 2008 | Interleukin Genetics | SEC FORM 4 Bought | $5951,700 at $0.35 | filing |
| 18 Nov 2008filed 20 Nov 2008 | Interleukin Genetics | SEC FORM 4 Bought | $41100 at $0.41 | filing |
| 18 Nov 2008filed 20 Nov 2008 | Interleukin Genetics | SEC FORM 4 Bought | $3,4448,200 at $0.42 | filing |
| 18 Nov 2008filed 20 Nov 2008 | Interleukin Genetics | SEC FORM 4 Bought | $5,00010,000 at $0.50 | filing |
News
No headline names them, or the companies they trade most, lately.